URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Daniel M. Junius net worth and biography

Daniel Junius Biography and Net Worth

Director of IDEXX Laboratories

Mr. Junius served as President and Chief Executive Officer of ImmunoGen, Inc. from 2009 until his retirement in May 2016. Before that, he served as President and Chief Operating Officer and Acting Chief Financial Officer from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008 and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and Chief Financial Officer of New England Business Services from 1998 to 2002. Before joining New England Business Services, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer of Nashua Corporation in 1996. Mr. Junius has been a director of GlycoMimetics, Inc. since March 2016. Mr. Junius served as a director of ImmunoGen, Inc. from November 2008 to June 2018. Mr. Junius was previously a director of Vitae Pharmaceuticals, Inc. from July 2016 until its acquisition by Allergan plc in October 2016. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a master’s degree in Management from Northwestern University’s Kellogg School of Management.

What is Daniel M. Junius' net worth?: The estimated net worth of Daniel M. Junius is at least $38.44 million as of May 10th, 2023. Mr. Junius owns 93,250 shares of IDEXX Laboratories stock worth more than $38,443,245 as of December 20th. This net worth estimate does not reflect any other investments that Mr. Junius may own. Learn More about Daniel M. Junius' net worth.
How do I contact Daniel M. Junius?: The corporate mailing address for Mr. Junius and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Daniel M. Junius' contact information.
Has Daniel M. Junius been buying or selling shares of IDEXX Laboratories?: Daniel M. Junius has not been actively trading shares of IDEXX Laboratories within the last three months. Most recently, Daniel M. Junius sold 3,046 shares of the business's stock in a transaction on Monday, December 5th. The shares were sold at an average price of $424.91, for a transaction totalling $1,294,275.86. Following the completion of the sale, the director now directly owns 2,968 shares of the company's stock, valued at $1,261,132.88. Learn More on Daniel M. Junius' trading history.
Who are IDEXX Laboratories' active insiders?: IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.
Are insiders buying or selling shares of IDEXX Laboratories?: During the last year, insiders at the sold shares 5 times. They sold a total of 44,068 shares worth more than $25,124,750.88. The most recent insider tranaction occured on November, 27th when Director Sophie V Vandebroek sold 344 shares worth more than $144,631.36. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.
Information on this page was last updated on 11/27/2024.

Daniel M. Junius Insider Trading History at IDEXX Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2022	Sell	3,046	$424.91	$1,294,275.86	2,968
8/10/2021	Sell	2,402	$679.58	$1,632,351.16
5/21/2021	Sell	2,500	$539.57	$1,348,925.00	658,701
8/20/2020	Sell	3,722	$382.61	$1,424,074.42	6,569
2/28/2018	Sell	2,974	$190.06	$565,238.44	5,602
2/8/2017	Sell	3,000	$141.75	$425,250.00	5,495

Daniel M. Junius Buying and Selling Activity at IDEXX Laboratories

IDEXX Laboratories Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Today's Range

Now: $412.26

$404.36

$418.26

50 Day Range

MA: $433.90

$406.92

$478.00

2 Week Range

Now: $412.26

$398.50

$583.39

Volume

1,122,179 shs

Average Volume

516,185 shs

Market Capitalization

$33.76 billion

P/E Ratio

39.76

Dividend Yield

N/A

Beta

1.37